2022ASCO前瞻|转移性非小细胞肺癌重磅研究一览
Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis.
KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12Cmutation.
Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing,EGFR-mutated non-small cell lung cancer (NSCLC).
临床试验,推荐有礼!
4W+麦粒等您来拿!
▼▼▼
名师课堂,扫码进入
▼▼▼
更多课程详见“医脉通知识银行”公众号